Truvada/Sustiva combo fails in second attempt

A second attempt to combine Truvada and Sustiva into a single HIV pill has failed, says Gilead Sciences. The failure will delay an application to the FDA until sometime next year, said Gilead, which saw its shares slide on the news this morning. A spokesperson for Gilead said that researchers plan to employ new technology in mixing the drugs in the next round. Gilead earns about $1.33 billion a year from the sale of HIV drugs.

- read this story from the Los Angeles Times for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.